Tyrosine Kinase Inhibitor Induced Proteinuria - A Review

被引:0
|
作者
Gayathri, J. S. [1 ]
Krishna, S. Swathi [1 ]
Rakesh, M. P. [2 ]
机构
[1] Amrita Vishwa Vidyapeetham, Amrita Sch Pharm, Dept Pharm Practice, Amrita Hlth Sci Campus, Kochi, India
[2] Amrita Vishwa Vidyapeetham, Dept Med Oncol, Amrita Hlth Sci Campus, Kochi, India
关键词
TKI; proteinuria; management; adverse effect; ENDOTHELIAL GROWTH-FACTOR; TYPE-1; DIABETIC-PATIENTS; EXPRESSION; RENOPROTECTION; VEGF; NEPHROPATHY; CARCINOMA; BLOCKADE; NEPHRIN;
D O I
10.1055/a-2423-3533
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tyrosine Kinase inhibitor (TKI) is a class of drugs that interfere with protein kinases' signal transduction pathways through an array of inhibitory mechanisms. Tyrosine kinases (TK) have an inevitable role in downstream signal transduction and the proliferation of tumour cells. Hence, tyrosine kinase inhibitors (TKIs) are frequently employed as anti-neoplastic agents in the treatment of colon, breast, kidney, and lung cancers. They can be used as single or combination therapy with other targeted therapies. It is understood that TKIs pose a risk of developing proteinuria in some patients as it can primarily result in dysfunction of the split diaphragm, constriction or blockage of capillary lumens mediated by the basement membrane, acute interstitial nephritis, or acute tubular necrosis. This paper reviews the mechanism of action of TKIs, the pathophysiological mechanism of TKI-induced proteinuria, and its management
引用
收藏
页码:5 / 11
页数:7
相关论文
共 50 条
  • [1] TYROSINE KINASE INHIBITOR AND MASSIVE PROTEINURIA
    Manley, Patrick
    Aung, Nyi
    NEPHROLOGY, 2024, 29 : 69 - 69
  • [2] Tyrosine Kinase Inhibitor Induced Thyrotoxicosis
    Bakerywala, Suhalia
    Schwarcz, Monica G. D.
    Goldberg, Michael David
    Valiquette, Guy
    Weiss, Irene A.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [3] Tyrosine Kinase Inhibitor-Induced Thyroid Disorders: A Review and Hypothesis
    Makita, Noriko
    Iiri, Taroh
    THYROID, 2013, 23 (02) : 151 - 159
  • [4] Tyrosine kinase inhibitor (TKI)-induced macrocytosis
    Schallier, D.
    Trullemans, F.
    Fontaine, C.
    Decoster, L.
    De Greve, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 136 - 136
  • [5] Tyrosine Kinase Inhibitor-Induced Hypertension
    Megha Agarwal
    Nidhi Thareja
    Melody Benjamin
    Andre Akhondi
    George D. Mitchell
    Current Oncology Reports, 2018, 20
  • [6] Tyrosine Kinase Inhibitor-Induced Hypertension
    Agarwal, Megha
    Thareja, Nidhi
    Benjamin, Melody
    Akhondi, Andre
    Mitchell, George D.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (08)
  • [7] Tyrosine kinase inhibitor (tki)-induced macrocytosis
    Schallier, D.
    Trullemans, F.
    Fontaine, C.
    Decoster, L.
    De Greve, J.
    ACTA CLINICA BELGICA, 2010, 65 (02): : 156 - 156
  • [8] Tyrosine Kinase Inhibitor-induced Macrocytosis
    Schallier, D.
    Trullemans, F.
    Fontaine, C.
    Decoster, L.
    De Greve, J.
    ANTICANCER RESEARCH, 2009, 29 (12) : 5225 - 5228
  • [9] PERICARDIAL EFFUSION INDUCED BY TYROSINE KINASE INHIBITOR RELATED HYPOTHYROIDISM PERICARDIAL EFFUSION INDUCED BY TYROSINE KINASE INHIBITOR RELATED HYPOTHYROIDISM
    Sut, D.
    Antonutti, M.
    Tioni, C.
    Pagura, L.
    Collini, V.
    De Biasio, M.
    Sinagra, G.
    Proclemer, A.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E91 - E91
  • [10] Proteinuria and hypertension with tyrosine kinase inhibitors
    Kandula, Praveen
    Agarwal, Rajiv
    KIDNEY INTERNATIONAL, 2011, 80 (12) : 1271 - 1277